Whitehawk Therapeutics (WHWK) versus Its Rivals Head-To-Head Comparison

Whitehawk Therapeutics (NASDAQ:WHWK) is one of 451 public companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its peers? We will compare Whitehawk Therapeutics to related businesses based on the strength of its profitability, risk, earnings, valuation, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Whitehawk Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	99.42%	-75.99%	-68.57%
Whitehawk Therapeutics Competitors	-2,625.49%	-359.63%	-43.39%

Insider & Institutional Ownership

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Whitehawk Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics’ peers have a beta of 10.34, meaning that their average share price is 934% more volatile than the S&P 500.

Earnings & Valuation

This table compares Whitehawk Therapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Whitehawk Therapeutics	$25.98 million	-$63.69 million	-39.50
Whitehawk Therapeutics Competitors	$439.20 million	-$68.89 million	-9.38

Whitehawk Therapeutics’ peers have higher revenue, but lower earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Whitehawk Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1	1	0	0	1.50
Whitehawk Therapeutics Competitors	4784	9958	15995	370	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 100.81%. Given Whitehawk Therapeutics’ peers stronger consensus rating and higher probable upside, analysts plainly believe Whitehawk Therapeutics has less favorable growth aspects than its peers.

Summary

Whitehawk Therapeutics peers beat Whitehawk Therapeutics on 8 of the 13 factors compared.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.